Anti-IL-17A Antibody Selection Guide: Clone Comparison for WB, ELISA, IHC & In Vivo

Interleukin-17A (IL-17A) is the signature effector cytokine of Th17 cells and the direct therapeutic target of approved biologics like secukinumab (Cosentyx), ixekizumab (Taltz), and bimekizumab (Bimzelx). Because IL-17A research spans everything from immunohistochemistry of psoriatic skin biopsies to preclinical antibody neutralization studies, no single anti-IL-17A antibody clone performs well across every application — a polyclonal optimized for Western blot is the wrong choice for in vivo dosing, and a flow cytometry conjugate won't give you clean IHC staining.

This guide breaks down IL-17A antibody selection by application — Western blot, ELISA, IHC, flow cytometry, and in vivo neutralization — and includes a clone comparison table so you can match the right reagent to your experimental design.

Choosing an Anti-IL-17A Antibody by Application

Western Blot, IHC & ELISA: Polyclonal Antibodies

For standard detection workflows — Western blot, immunohistochemistry, and ELISA — a polyclonal antibody remains the workhorse choice. Polyclonals recognize multiple epitopes on IL-17A, which improves detection sensitivity across fixation methods and blot conditions, at some cost to lot-to-lot consistency compared to monoclonals.

Flow Cytometry: Directly Conjugated Recombinant Monoclonals

For intracellular cytokine staining and flow-based IL-17A detection, recombinant monoclonal antibodies with defined clone identity (rather than polyclonals) give more reproducible gating across experiments. abinScience's SAA0386 (mouse-host) and SAA0387 (human-host) recombinant clones are each available pre-conjugated to FITC, PE, APC, or PerCP, letting you build a multi-color panel without in-house conjugation.

In Vivo Neutralization: InVivoMAb and InVivo Plus Grades

Antibodies intended for in vivo blocking or neutralization studies require a different manufacturing standard entirely — azide-free formulation and tightly controlled endotoxin are essential to avoid confounding immune activation in animal models.

Biosimilar Benchmarking: Reference Antibodies

If your work involves comparing a candidate biologic against approved or investigational anti-IL-17 therapeutics, a reference antibody reproduces the originator's binding profile for ELISA, FACS-based bioactivity, and functional assay benchmarking. abinScience's newly added Bimekizumab reference antibody joins an existing panel covering secukinumab, ixekizumab, netakimab, and other IL-17A/F-targeting biologics — useful for both dual IL-17A/IL-17F neutralization studies and competitive landscape research.

Anti-IL-17A Clone Comparison Table

For the complete set of 119 IL-17A-related products — including additional biosimilar reference antibodies (secukinumab, ixekizumab, netakimab, vunakizumab, and others) and bispecific reference antibodies co-targeting IL-17A with TNF-α or albumin — browse the full IL-17A catalog →

Newly Added: Mouse IL-17A Protein & Bimekizumab Reference Antibody

Two recent catalog additions round out the IL-17A toolkit: a Mouse IL17A Recombinant Protein (C-His), catalog MS856011, useful as an immunogen control or ELISA standard for mouse-reactive assays, and the Bimekizumab reference antibody (HS856036) — the RUO reference standard for bimekizumab, the first approved biologic to dually neutralize IL-17A and IL-17F, positioning it for both psoriasis/psoriatic arthritis research and dual-cytokine mechanism studies.